Autologous anti-CD19 chimeric antigen receptor T-cell therapy (Malaghan Institute of Medical Research)

N/A

Report date: 2026/05/07 20:00:36

Base Information

Drug NameAutologous anti-CD19 chimeric antigen receptor T-cell therapy (Malaghan Institute of Medical Research)
Drug Alias Name1928T2z CAR-T cell therapy自体抗CD19嵌合抗原受体T细胞疗法-马拉根医学研究所Autologous Third-generation Anti-CD19 Chimeric Antigen Receptor T-cell therapy1928T2z CAR-T cellsAutologous Third-generation Anti-CD19 Chimeric Antigen Receptor T-cells +[8] 
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-CD19
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsPrimary mediastinal B cell lymphomaLymphoma, Mantle-CellLymphoma, Follicular +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryNew Zealand
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesThe Malaghan Institute Of Medical Research
China Registration ClassN/A

Develop Information

Active CompaniesBioOra LtdWellington Zhaotai Therapies LtdThe Malaghan Institute Of Medical Research
Inactive CompaniesN/A
Active IndicationsPrimary mediastinal B cell lymphomaLymphoma, Mantle-CellLymphoma, Follicular +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A